Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Zack Kubow - Real Chemistry Leiv Lea - CFO Richard Miller - CEO Jim Rosenbaum - SVP of Research Conference Call Participants Aydin Huseynov - Ladenberg Jeff Jones - Oppenheimer Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2023 Business Update and Financial Results Conference Call. At this time, all p ...

Financial Position - As of September 30, 2023, the company had cash, cash equivalents, and marketable securities of $32.2 million, down from $42.3 million as of December 31, 2022, with an accumulated deficit of $328.1 million[226]. - The company reported an increase in interest income of $0.2 million for the three months ended September 30, 2023, due to rising interest rates[217]. - Cash provided by financing activities amounted to $7.9 million during the nine months ended September 30, 2023, primarily from net proceeds of common stock issuance through the at-the-market offering program[261]. Clinical Development - The company completed an End-of-Phase/Pre-Phase 3 meeting with the FDA in August 2023, anticipating to initiate a Phase 3 clinical trial of soquelitinib in early 2024, enrolling 150 patients with relapsed PTCL[189]. - The company plans to initiate a Phase 1 clinical trial of soquelitinib in solid tumors in the first half of 2024, based on preclinical findings suggesting enhanced anti-tumor immunity[192]. - The company is collaborating with the Kidney Cancer Research Consortium to evaluate ciforadenant in a Phase 1b/2 clinical trial for metastatic renal cell cancer, with interim data expected in early 2024[215]. - In the 200 mg cohort of the Phase 1/1b clinical trial, as of May 18, 2023, there were 3 complete responses (CRs) and 3 partial responses (PRs) among 20 evaluable patients[188]. - The 200 mg dose of soquelitinib was determined to be optimal, showing higher response rates and longer disease control in patients[202]. - Preclinical data for soquelitinib indicated in vivo anti-tumor activity across several mouse tumor models, including colon, renal, melanoma, and both B cell and T cell tumors[235]. - Soquelitinib demonstrated a dose-dependent Th1 skewing and Th2 blockade in vitro, supporting the selection of a 200 mg dose for further studies[233]. - The company is evaluating the potential registrational clinical trial for soquelitinib, alongside other product candidates like ciforadenant and mupadolimab[238]. Expenses and Income - For the nine months ended September 30, 2023, general and administrative expenses decreased by $1.3 million compared to the same period in 2022, primarily due to a $0.6 million decrease in personnel costs[216]. - For the nine months ended September 30, 2023, the company recognized a decrease in sublease income of $0.4 million due to the expiration of the sublease agreement with Angel Pharmaceuticals in January 2023[218]. - The company reported a decrease in sublease income of $0.1 million due to the expiration of a building sublease agreement with Angel Pharmaceuticals in January 2023[237]. - Corvus Pharmaceuticals reported total operating lease costs of $418,000 for the three months ended September 30, 2023, compared to $414,000 for the same period in 2022, reflecting a slight increase of 1%[236]. - The company incurred research and development costs of $306,000 for the three months ended September 30, 2023, consistent with the previous year, while total operating lease costs for the nine months ended September 30, 2023, were $1.226 million, up from $987,000 in 2022, representing a 24% increase[236]. Risks and Compliance - Corvus Pharmaceuticals is exposed to risks related to compliance with healthcare laws, which could result in significant penalties if violations occur[246]. - The remaining lease term for operating leases is 1.3 years as of September 30, 2023, down from 2.3 years in the previous year[236]. - The company expects to increase spending related to the development and commercialization of its product candidates, funded through equity and/or debt financings[227]. - Corvus Pharmaceuticals is focusing on the development of immune modulator product candidates aimed at treating solid cancers and T cell lymphomas, with three candidates currently in clinical development[232].

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2023 Earnings Call Transcript August 8, 2023 4:30 PM ET Company Participants Zack Kubow - IR-Real Chemistry Leiv Lea - CFO Richard Miller - CEO Conference Call Participants Roger Song - Jefferies Aydin Huseynov - Ladenburg Thalmann Rosemary Li - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Thank you for standing by. This is the conference operator. Welcome to the Corvus Pharmaceuticals Second Quarter 2023 Conference Call. [Operator Instructions]. I would ...

FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Emerging growth company ☐ TABLE OF CONTENTS | --- | --- | |----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Data and Key Metrics Changes - The net loss for the first quarter of 2023 was $7.9 million, a slight improvement from a net loss of $8.3 million in the same period in 2022 [48] - Cash, cash equivalents, and marketable securities totaled $34.5 million as of March 31, 2023, down from $42.3 million at the end of 2022 [49] - Research and development expenses decreased to $4.6 million in Q1 2023 from $5.1 million in Q1 2022, reflecting a focus on managing cash burn [3][4] Business Line Data and Key Metrics Changes - The ongoing Phase 1/1b trial of CPI-818 in T cell lymphoma has shown promising results, with two complete responses and three partial responses among 19 evaluable patients [15][19] - The median progression-free survival (PFS) for patients with an absolute lymphocyte count (ALC) above 900 was reported at 19.9 months, compared to just 2.1 months for those below 900 [69] Market Data and Key Metrics Changes - The company is preparing for a meeting with the FDA in Q3 2023 to discuss a Phase 3 clinical trial for CPI-818, which is expected to include approximately 150 patients [5][14] - The company is also focused on expanding the application of CPI-818 beyond T cell lymphoma to solid tumors, supported by recent preclinical data [7][10] Company Strategy and Development Direction - The company is prioritizing CPI-818 as its most advanced ITK inhibitor, aiming for a potential registration trial for T cell lymphoma [10][50] - There is an emphasis on establishing collaborations to support the development of product candidates and managing cash burn effectively [4][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential of CPI-818 to address unmet needs in cancer treatment [10][19] - The company plans to present additional interim data at the International Conference on Malignant Lymphoma in June 2023, which may further validate the efficacy of CPI-818 [51][60] Other Important Information - The company has extended its intellectual property covering CPI-818, with patents issued in multiple countries [17] - The safety profile of CPI-818 appears favorable, with no dose-limiting toxicities observed in trials [53] Q&A Session Summary Question: What is the expected design for the Phase 3 trial with the FDA? - Management expects to discuss the trial design and standard therapies in the control arm, with a focus on a randomized controlled trial [74][75] Question: What are the historical response rates for the control agents? - The overall response rate (ORR) for standard agents is about 25%, with short-lived responses [76] Question: Will there be an interim look at the data for response rates? - Management confirmed plans for an interim look at the data, consistent with recent FDA guidelines [43] Question: What is the plan for CPI-818 in immune diseases? - The company is still considering whether to move into immune diseases with CPI-818, depending on progress in cancer indications [91] Question: Is there any delay in the ciforadenant trial? - Management clarified that there is no slowdown in the ciforadenant trial, which is actively enrolling patients [92]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commissio ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President & Chief Executive Officer James Rosenbaum - Senior Vice President-Research Conference Call Participants Mara Goldstein - Mizuho Roger Song - Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commission Fil ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President & Chief Executive Officer James Rosenbaum - Senior Vice President-Research Conference Call Participants Jerry Gong - Mizuho Securities Roger Song - Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmace ...

Table of Contents- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Comm ...